. Specifically, RIG-I and MDA5 function as cytosolic receptors for viral 5Ј-triphosphate single-stranded RNA and double-stranded RNA (dsRNA), respectively, whereas NOD1 and NOD2 act as intracellular sensors for bacterial peptidoglycans (5) (6) (7) (8) . Upon ligand binding and activation, these intracellular pattern recognition receptors (PRRs) interact through their CARDs with downstream CARD-containing molecules to ultimately initiate a signaling cascade, resulting in the production of IFN-␣/␤ and inflammatory cytokines to limit viral or bacterial proliferation (9, 10) .
RIG-I and MDA5 consist of two N-terminal CARDs, a central DECH box ATPase domain, and a C-terminal regulatory/repressor domain (RD) (11, 12) . Whereas the C-terminal RD of RIG-I binds viral RNA in a 5Ј-triphosphate-dependent manner and activates the central ATPase by RNA-dependent dimerization (13, 14) , the CARDs of RIG-I trigger the interaction with its downstream partner MAVS/VISA/IPS-1/Cardif (15) (16) (17) (18) . The crucial role of the tandem CARD for RIG-I downstream signaling is further evidenced by the finding that the hepatocyte cell line Huh7.5, which carries the T 55 I mutation in the RIG-I first CARD, strongly supports hepatitis C virus (HCV) replication (19) . The T 55 I mutation disrupts the signaling function of the RIG-I CARDs to induce antiviral IFN production, leading to a high permissiveness to HCV replication. Furthermore, we have recently shown that the CARDs of RIG-I interact with the C-terminal SPRY domain of tripartite motif 25 (TRIM25) E3 ligase, and this interaction effectively delivers the K63-linked ubiquitin moieties to the RIG-I second CARD, resulting in a marked increase of RIG-I downstream signaling activity (20) . RIG-I Lys-172 (K 172 ) is critical for TRIM25-mediated ubiquitination and MAVS/VISA/IPS-1/Cardif binding, as well as the ability of RIG-I to induce antiviral signal transduction.
Unbalanced, continuous production of IFNs and inflammatory cytokines could lead to deleterious effects on host immunity. To tightly regulate the on/off switch of RIG-I-mediated innate immunity, RIG-I activity is negatively regulated by several mechanisms, including K48-linked ubiquitination leading to RIG-I degradation (21) and the LGP2 helicase protein, which lacks the N-terminal CARDs (22, 23) . In addition, alternative splicing has been identified as an important cellular regulatory mechanism in fine-tuning host IFN signaling activity. For instance, the alternatively spliced variants of NOD2 and MyD88 function as dominant-negative inhibitors of NOD2 and TLR-induced signal transduction, respectively (24) (25) (26) .
Here, we describe the distinct roles of the CARDs of RIG-I for TRIM25-binding and TRIM25-mediated ubiquitination and identify an alternatively spliced variant of RIG-I as a potential feedback inhibitor of its signal transduction, thereby unveiling the intricate regulation of RIG-I-mediated antiviral innate immunity. fusion constructs were tested for TRIM25 binding. GST-pulldown indicated that GST-RIG-I first CARD and GST-RIG-I 2CARD strongly bound full-length TRIM25 and TRIM25-SPRY, whereas GST and GST-RIG-I second CARD showed no interactions ( Fig.  1 A and B) . Regardless of TRIM25 binding, however, neither GST-RIG-I first CARD nor GST-RIG-I second CARD showed any detectable level of ubiquitination and MAVS-CARD-prolinerich-domain (PRD) interaction, whereas GST-RIG-I 2CARD underwent robust ubiquitination and efficiently interacted with MAVS-CARD-PRD under the same conditions [ Fig. 1C and supporting information (SI) Fig. S1 A] . In correlation with their lack of ubiquitination and MAVS binding, each CARD of RIG-I was incapable of activating the IFN-␤ and NF-B promoters ( Fig. 1D and Fig. S1B ). These results indicate that, whereas the first CARD is responsible for TRIM25 binding, the intact tandem CARD of RIG-I is necessary for TRIM25-mediated ubiquitination, ultimately allowing efficient MAVS interaction and downstream signal transduction. Binding. The T 55 I mutation of RIG-I first CARD abolishes RIG-I-mediated antiviral activity, leading to a high permissiveness to HCV replication (19) . However, the molecular mechanism by which the T 55 I mutation abrogates RIG-I-mediated antiviral signal transduction has not yet been illustrated. We found that the RIG-I T 55 I mutation abolished its TRIM25 binding ability, leading to the loss of TRIM25-induced RIG-I ubiquitination ( Fig. 2 A and B and Fig. S2 A) . Consistently, ectopic expression of TRIM25 efficiently enhanced the activity of GST-RIG-I 2CARD WT but not GST-RIG-I 2CARD T 55 I in inducing IFN-␤ promoter activation (Fig.  2C) . To examine the capability of RIG-I 2CARD T 55 I for interacting with MAVS, several previously described (20) GST-RIG-I 2CARD mutants were included in this assay: GST-RIG-I 2CARD K 172 R, in which the main ubiquitination site is mutated, GST-RIG-I 2CARD K 99/169/172/181/190/193 R, in which all six ubiquitination sites are mutated, and GST-RIG-I 2CARD K 172only , containing five K 3 R substitutions while leaving K 172 intact (Fig. 2D) . GST-RIG-I 2CARD T 55 I, K 172 R, and K 99/169/172/181/190/193 R mutants that did not undergo ubiquitination bound poorly to MAVS-CARD-PRD, whereas GST-RIG-I 2CARD WT and K 172only , which were heavily ubiquitinated, interacted strongly with MAVS-CARD-PRD (Fig.  2D ). This indicates that TRIM25-mediated ubiquitination of RIG-I is necessary for efficient interaction with MAVS. Indeed, MAVS-CARD-PRD displayed a higher binding affinity to the ubiquitinated form of the RIG-I 2CARD than the unmodified form (Fig.  S2B) . Furthermore, shRNA-mediated TRIM25 knockdown markedly suppressed the interaction between RIG-I 2CARD and MAVS-CARD-PRD (Fig. S2C ). These results demonstrate that the T 55 residue of the RIG-I first CARD is critical for TRIM25 binding and subsequently TRIM25-mediated ubiquitination, which is ultimately necessary for efficient RIG-I-MAVS interaction.
Because the T 55 or S 55 residue of RIG-I is highly conserved among various species, the potential phosphorylation of this residue might trigger TRIM25 interaction. To test this hypothesis, we introduced a series of point mutations in place of T 55 : T 55 E to mimic constitutive phosphorylation and T 55 I, T 55 A, and T 55 Q to mimic nonphosphorylation. The GST-RIG-I 2CARD mutants were then tested for TRIM25 binding, ubiquitination, and downstream signaling activity ( Fig. 2 E and F) . As shown in Fig. 2E , GST-RIG-I 2CARD T 55 Q and T 55 E exhibited an apparent reduction of TRIM25 binding and ubiquitination compared with GST-RIG-I 2CARD WT, whereas GST-RIG-I 2CARD T 55 A showed a similar extent of TRIM25 binding and ubiquitination compared with GST-RIG-I 2CARD WT. Furthermore, mass spectrometry analysis of purified GST-RIG-I 2CARD WT in the presence of phosphatase inhibitors showed no detectable phosphorylation or other known modifications at the T 55 residue (data not shown). In addition, the levels of TRIM25 binding and ubiquitination of these mutants directly correlated with their ability to induce IFN-␤ and NF-B promoter activation (Fig. 2F) .
Given that mutation of the RIG-I T 55 residue to the hydrophobic amino acid isoleucine abolished TRIM25 interaction, CARD ubiq- uitination, and RIG-I downstream signaling, we addressed whether altering hydrophobicity at the T 55 residue might interfere with TRIM25 binding and RIG-I signaling. Accordingly, the T 55 residue of RIG-I was replaced with tryptophan (T 55 W) or valine (T 55 V). GST-RIG-I 2CARD T 55 W and GST-RIG-I 2CARD T 55 V showed no detectable TRIM25 binding or ubiquitination and exhibited a near complete loss of signaling activity in inducing IFN-␤ or NF-B promoter activation ( Fig. S3 A and B) . These results collectively indicate that the lack of antiviral activity of the RIG-I T 55 I mutant is due to the loss of its ability to bind TRIM25.
Identification of RIG-I SV.
Given that the RIG-I first and second CARD are essential for TRIM25 binding and TRIM25-mediated ubiquitin attachment, respectively, we postulated that alternative splicing in the N-terminal tandem CARD of RIG-I might affect its ubiquitination-dependent signaling function. To test this hypothesis, we isolated total RNAs from mock-or IFN-␤-treated HEK293T cells and performed RT-PCR using primers that specifically amplified the RIG-I CARDs (exons 1-3) (Fig. 3B Upper) . In addition to the band corresponding to the expected size for the RIG-I CARDs sequence (735 bp), a band with a smaller size (603 bp) was detected in IFN-␤-treated, but not in mock-treated HEK293T cells (Fig. 3B ). Cloning and sequence analysis of the smaller amplicon identified a RIG-I SV that lacked the exon 2, coding for amino acids 36-80 of RIG-I. Additional RT-PCR analysis using primers to specifically amplify the complete ORF of RIG-I (exons 1-18) also identified the alternatively spliced variant of RIG-I carrying the deletion of exon 2 (Fig. 3A) . We further tested the expression patterns of full-length RIG-I and the SV in mock-treated versus IFN-␤-treated or Sendai virus (SeV)-infected HEK293T cells, using primers specific for fulllength RIG-I or the SV (Fig. 3B and Fig. S4A) . Whereas a low level of full-length RIG-I mRNA was detected in mock-treated cells, the RIG-I SV was undetectable under the same conditions ( Fig. 3B and Fig. S4A ). Furthermore, the transcript levels of both full-length RIG-I and the SV significantly increased upon IFN-␤ treatment or SeV infection. Additionally, the RIG-I SV was detectable in a number of cell lines upon IFN-␤ treatment, including lymphatic endothelial cells (LECs), HeLa, HCT116, Huh7, LnCap, and NHLF lung fibroblast cells, but not after treatment with all-trans retinoic acid (Figs. S4B and S5A) , indicating an IFN stimulationspecific expression of the RIG-I SV. In line with this, the RIG-I SV was readily detectable in 2fTGH WT human fibroblasts but not in STAT1-deficient (U3A) nor STAT2-deficient (U6A) cells upon treatment with IFN-␣ or IFN-␤ (Fig. S5B) . Furthermore, a monoclonal RIG-I antibody that reacted with the central helicase domain readily detected a 100-kDa band in addition to the 116-kDa band corresponding to full-length RIG-I in IFN-␤-treated or SeVinfected HEK293T cells but not in mock-treated cells (Fig. 3B and  Fig. S4A ). This 100-kDa band comigrated with exogenously expressed Flag-tagged RIG-I SV (Fig. S4A) . Furthermore, a RIG-I antibody generated by the peptide containing residues 37-55 detected the 116-kDa full-length RIG-I but not the 100-kDa SV (Fig.  S4C) . These results indicate that RIG-I undergoes alternative splicing upon IFN stimulation, resulting in an isoform that lacks the short sequence of the first CARD containing the T 55 residue.
Lack of TRIM25 Binding, Ubiquitination, and Signaling Activity of RIG-I SV. To study the potential role of the RIG-I SV in antiviral signal transduction, GST-RIG-I 2CARD SV was tested for a series of biochemical activities: TRIM25 binding, ubiquitination, MAVS binding, and downstream signal transducing ability. Like the GST-RIG-I 2CARD T 55 I mutant (Fig. 2) , GST-RIG-I 2CARD SV was unable to bind TRIM25 full-length and TRIM25-SPRY at detect- WT, or GST-RIG-I 2CARD T 55I together with TRIM25-V5 WCLs were used for GST-PD, followed by IB with ␣-V5 or ␣-GST. Arrows indicate the ubiquitinated bands. (B and C) T 55I mutation abolishes RIG-I CARD ubiquitination and downstream signaling. GST-RIG-I 2CARD WT or GST-RIG-I 2CARD T55I with or without TRIM25-V5 was expressed in HEK293T. WCLs were used for GST-PD, followed by IB with ␣-GST or ␣-Ub. Arrows indicate the ubiquitinated bands. (C) GST-RIG-I 2CARD WT or T55I with or without TRIM25 together with IFN-␤ luciferase and pGK-␤-gal were expressed in HEK293T cells as described in Fig. 1D . Data represent the mean Ϯ SD (n ϭ 3). (D) T55I mutation strongly decreases RIG-I binding to MAVS. HEK293T were transfected with MAVS-CARD-PRD-Flag together with GST or GST-RIG-I 2CARD fusion constructs. WCLs were subjected to GST-PD, followed by IB with ␣-Flag, ␣-Ub, or ␣-GST. MAVS-CARD-PRD expression was determined by IB with ␣-Flag. (E and F) Ubiquitination, TRIM25 binding, and signaling activity of RIG-I 2CARD T 55 mutants. GST or GST-RIG-I 2CARD was expressed in HEK293T cells. WCLs were subjected to GST-PD, followed by IB with ␣-Ub, ␣-GST, or ␣-TRIM25. Arrows indicate the ubiquitinated bands. Luciferase assay was performed as described in Fig. 1D . Data represent the mean Ϯ SD (n ϭ 3).
able levels and did not undergo TRIM25-mediated ubiquitination ( Fig. 3C and Fig. S6A ). Consistently, full-length RIG-I SV showed no detectable TRIM25 binding and extremely low K 63 -linked ubiquitination ( Fig. S6 B and C) . Furthermore, whereas GST-RIG-I 2CARD T 55 I, K 172 R or K 99/169/172/181/190/193 R mutants bound poorly to MAVS-CARD-PRD compared with GST-RIG-I 2CARD WT, GST-RIG-I 2CARD SV showed no interaction with MAVS-CARD-PRD (Fig. 3D) . Finally, GST-RIG-I 2CARD SV was incapable of inducing IFN-␤ or NF-B promoter activation in the presence or absence of exogenous TRIM25 (Fig. 3E and  Fig. S6D ).
To further test the antiviral activity of the RIG-I SV upon viral infection, we tested the replication of enhanced-GFP-containing vesicular stomatitis virus (VSV-eGFP) in RIG-I Ϫ/Ϫ mouse embryonic fibroblasts (MEFs) expressing vector, RIG-I WT, RIG-I SV, or RIG-I T 55 I mutant. RIG-I WT expression drastically suppressed VSV-eGFP replication: VSV-eGFP titer was Ϸ200-fold lower in RIG-I WT-expressing cells than in vector-containing cells (Fig. 3F) . In contrast, MEFs expressing the RIG-I SV or RIG-I T 55 I mutant had similar viral titers to MEFs expressing vector only (Fig.  3F) . Thus, the RIG-I SV, lacking a critical part of the first CARD, loses TRIM25 binding, which subsequently abolishes TRIM25-mediated ubiquitination and MAVS binding and, thereby, antiviral activity.
RIG-I SV Acts as a Dominant Inhibitor of RIG-I-Mediated Antiviral IFN
Response. To explore the effects of the RIG-I SV on RIG-I signal transduction, HEK293T cells were transfected with IFN-␤ or NF-B promoter luciferase together with increasing amounts of Flag-RIG-I SV, followed by SeV infection (Fig. 4A and Fig. S7 ).
RIG-I T 55 I mutant was included as a control. Although both RIG-I SV and RIG-I T 55 I mutant markedly suppressed the SeV-induced IFN-␤ or NF-B promoter activation, the level of suppression induced by RIG-I SV was markedly stronger than that induced by RIG-I T 55 I mutant (Fig. 4A and Fig. S7 ). In addition, the exogenously expressed RIG-I SV potently inhibited SeV-induced IFN-␤ promoter activation in HCT116, Huh7, and HeLa cells (Fig. S8) .
To further delineate the inhibitory effect of the RIG-I SV on the RIG-I-mediated downstream signaling cascade, we examined virusinduced phosphorylation, dimerization, and nuclear translocation of IFN regulatory factor 3 (IRF3). HEK293T cells were cotransfected with Myc-tagged RIG-I WT together with vector, Flag-RIG-I SV or RIG-I T 55 I mutant followed by SeV infection. This showed that SeV infection led to a considerable shift of endogenous IRF3 to the slow-migrating phosphorylated forms that were also readily detected by anti-S 396 phospho-specific IRF3 antibody (Fig.  4B) . In contrast, ectopic expression of RIG-I SV and RIG-I T 55 I mutant strongly suppressed the SeV-induced phosphorylation of IRF3 (Fig. 4B) . In addition, RIG-I SV and RIG-I T 55 I mutant almost completely blocked SeV-induced IRF3 dimerization (Fig.  4C) . We further tested the nuclear translocation of IRF3-eGFP induced by SeV infection in HEK293T stably expressing vector, RIG-I WT, RIG-I SV, or RIG-I T 55 I mutant. Although the nuclear translocation of IRF3-eGFP was apparently detected in HEK293T cells expressing vector or RIG-I WT upon SeV infection, it was not observed in cells expressing RIG-I SV or RIG-I T 55 I mutant (Fig.  4D) . Finally, RIG-I SV and RIG-I T 55 I mutant expression detectably increased VSV-eGFP replication compared with vector expression. In contrast, RIG-I WT expression markedly decreased VSV-eGFP replication (Fig. 4E) . Furthermore, HEK293T cells expressing RIG-I SV or RIG-I T 55 I mutant showed reduced amounts of secreted IFN-␤ upon SeV infection compared with cells expressing vector or RIG-I WT (Fig. 4F) . These results collectively indicate that the RIG-I SV acts as a dominant inhibitor of the RIG-I-mediated antiviral response, possibly serving as a negativefeedback mechanism.
Inhibition of RIG-I Multimerization and RIG-I-MAVS Signaling Complex
Formation by RIG-I SV. To decipher the molecular mechanism of how the SV inhibits RIG-I-mediated IFN signal transduction, we tested RIG-I SV mutants in their ability to suppress the SeVinduced IFN induction: RIG-I SV K 270 A mutant with the loss of ATPase activity (11) and RIG-I SV C 810,813 A with the abolished RD structure (13) . Although RIG-I SV and RIG-I SV K 270 A strongly inhibited the SeV-induced IFN-␤ promoter activation, RIG-I SV C 810 , 813 A did not show any significant inhibitory effect (Fig. 5A) , indicating that the intact structure of the C-terminal RD is critical for the inhibitory effect of RIG-I SV.
The C-terminal RD of RIG-I specifically binds 5Ј-triphosphate viral RNA, and this interaction triggers RNA-dependent RIG-I dimerization. Therefore, the RIG-I SV was tested for its ability to bind 5Ј-triphosphate viral RNA and to interact with RIG-I WT. Fluorescence anisotropy analysis showed that RIG-I WT and RIG-I SV had similar binding affinities to in vitro-transcribed 5Ј-triphosphate containing rabies virus leader RNA (5ЈpppRVL): WT (K d ϭ 246.41 nM) and SV (K d ϭ 233.39 nM) (Fig. S9A) . Furthermore, RIG-I SV readily interacted with RIG-I WT in the presence and absence of viral infection, and this interaction detectably inhibited RIG-I multimerization in a dose-dependent manner ( Fig. 5 B and C and Fig. S9B ). Finally, ectopic expression of the RIG-I SV and RIG-I T 55 I led to a considerable reduction of RIG-I WT interaction with MAVS-CARD-PRD or full-length MAVS induced by SeV infection (Fig. 5D and Fig. S9C ). These results indicate that the RIG-I SV interacts with RIG-I WT, and this interaction efficiently inhibits RIG-I multimerization and RIG-I-MAVS-interaction, resulting in a potent inhibition of virus-induced IFN signal transduction.
Discussion
A previous study (19) has shown that the naturally occurring T 55 I mutation of the RIG-I first CARD in the hepatocyte Huh7.5 cells disrupts the signaling activity of the CARDs, resulting in a high permissiveness to HCV replication. Our data revealed that the T 55 I mutation of the RIG-I first CARD completely abolished its ability to bind TRIM25, leading to the loss of RIG-I CARD ubiquitination and signaling activity.
The essence of the intact tandem CARD for RIG-I ubiquitination-dependent activity is further evidenced by the identification of a novel RIG-I SV whose expression is induced upon viral infection or IFN stimulation. Because of a short deletion in its first CARD, the RIG-I SV is unable to carry out TRIM25 interaction, ubiquitination, and, ultimately, antiviral signal transduction. Besides its lack of signaling activity, this SV acts as an endogenous inhibitor of RIG-I signal transduction, possibly providing a negative-feedback inhibition or fine-tuning mechanism.
The RIG-I C-terminal RD contains the highly conserved Cys 810 -, Cys 813 -, Cys 864 -, and Cys 869 -comprising zinc-coordination site as a key structural element for its functional activities (13) . Our data showed that the structural integrity of the RD is critical for the inhibitory activity of the RIG-I SV, because the C 810 , 813 A mutant no longer inhibited virus-induced IFN signal transduction. Upon binding to viral RNA, the RIG-I RD triggers a structural switch to induce the RNA-dependent RIG-I dimerization (13) . Because RIG-I WT and the RIG-I SV exhibited similar binding affinities to 5Ј-triphosphate RNA, viral RNA-sequestration may not serve as the main mechanism of the inhibitory effect of the RIG-I SV on virus-induced IFN signal transduction. The RIG-I SV, instead, efficiently interacted with RIG-I WT to form a RIG-I WT-RIG-I SV heterocomplex, and this interaction suppressed RIG-I WT multimerization as well as RIG-I-MAVS interaction that are critical for RIG-I signaling.
Cui et al. (13) have suggested a potential model for the Cterminal RD-dependent RIG-I activation. In the absence of viral infection, RIG-I is monomeric and inactive by masking the central DECH domain with its N-terminal CARDs. Upon viral 5Ј pppRNA interaction, the RD undergoes a conformational change and dimerizes, displacing the CARDs. Our study also suggests the multiple steps of the N-terminal CARD-dependent RIG-I activation. Upon viral RNA binding, the RIG-I first CARD is exposed and binds TRIM25 that subsequently ubiquitinates the lysine residues of the RIG-I second CARD. The ubiquitinated RIG-I CARDs effectively interact with MAVS, eliciting downstream antiviral signal transduction to induce IFN-␣/␤ production.
Materials and Methods
Native PAGE. Native PAGE was performed by using a 7.5% acrylamide gel (Bio-Rad). The gel was prerun with 25 mM Tris and 192 mM glycine (pH 8.4) with or without 0.7% deoxycholate in the cathode and anode chamber, respectively, for 30 min at 30 mA. Samples in the native sample buffer [62.5 mM Tris⅐HCl (pH 6.8), 15% glycerol] were applied on the gel and electrophoresed for 40 -80 min at 10 mA, followed by immunoblotting.
Confocal Immunofluorescence Microscopy.
Cell preparation and confocal microscopy analysis were performed as described (20) .
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